regulatory
confidence high
sentiment negative
materiality 0.75
Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days
LeonaBio, Inc.
- Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.
- Has 180 calendar days (until April 14, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
- May seek stockholder approval for reverse stock split if needed to cure deficiency.
- Also plans to file new $300M shelf registration S-3 to replace expiring 2021 registration.
- If not compliant by deadline, may transfer to Nasdaq Capital Market for additional 180-day cure period.